Pediatrix Medical Group (NYSE:MD) Upgraded at StockNews.com

StockNews.com upgraded shares of Pediatrix Medical Group (NYSE:MD) from a hold rating to a buy rating in a research note issued to investors on Thursday morning.

MD has been the subject of several other reports. Jefferies Financial Group increased their price target on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. UBS Group lifted their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Truist Financial cut their price target on shares of Pediatrix Medical Group from $16.00 to $15.00 and set a “hold” rating for the company in a report on Monday, January 6th. Mizuho lifted their price objective on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Pediatrix Medical Group presently has an average rating of “Hold” and a consensus price target of $16.25.

Pediatrix Medical Group Trading Down 2.1 %

Shares of Pediatrix Medical Group stock opened at $12.46 on Thursday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. The company has a market capitalization of $1.07 billion, a P/E ratio of -4.07, a PEG ratio of 2.00 and a beta of 1.58. Pediatrix Medical Group has a 1 year low of $6.62 and a 1 year high of $16.41. The company’s fifty day moving average is $14.30 and its two-hundred day moving average is $11.60.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The firm had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The business’s revenue was up .9% on a year-over-year basis. During the same quarter last year, the company posted $0.29 earnings per share. Analysts forecast that Pediatrix Medical Group will post 1.26 earnings per share for the current year.

Insider Activity

In other news, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the sale, the director now directly owns 138,683 shares in the company, valued at $2,128,784.05. This represents a 16.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mary Ann E. Moore sold 8,108 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.00% of the company’s stock.

Institutional Investors Weigh In On Pediatrix Medical Group

Large investors have recently bought and sold shares of the stock. State Street Corp lifted its position in shares of Pediatrix Medical Group by 1.4% in the third quarter. State Street Corp now owns 3,540,791 shares of the company’s stock valued at $41,038,000 after acquiring an additional 50,597 shares in the last quarter. Aristeia Capital L.L.C. purchased a new position in Pediatrix Medical Group in the 2nd quarter valued at about $687,000. Barclays PLC boosted its stake in shares of Pediatrix Medical Group by 302.9% during the 3rd quarter. Barclays PLC now owns 142,087 shares of the company’s stock worth $1,646,000 after purchasing an additional 106,817 shares during the last quarter. Franklin Resources Inc. purchased a new stake in shares of Pediatrix Medical Group during the third quarter worth about $598,000. Finally, Principal Financial Group Inc. grew its holdings in shares of Pediatrix Medical Group by 14.1% during the third quarter. Principal Financial Group Inc. now owns 513,618 shares of the company’s stock worth $5,953,000 after buying an additional 63,581 shares in the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.